Literature DB >> 12878542

Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.

Luiz E Bermudez1, Robert Reynolds, Peter Kolonoski, Pricilla Aralar, Clark B Inderlied, Lowell S Young.   

Abstract

In vitro screening of thiacetazone derivatives indicated that two derivatives, SRI-286 and SRI-224, inhibited a panel of 25 Mycobacterium avium complex (MAC) isolates at concentrations of 2 micro g/ml or lower. In mice, SRI-224 and thiacetazone had no significant activity against the MAC in livers and spleens, but treatment with SRI-286 resulted in significant reduction of bacterial loads in livers and spleens. A combination of SRI-286 and moxifloxacin was significantly more active than single drug regimens in liver and spleen.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12878542      PMCID： PMC166073          DOI： 10.1128/AAC.47.8.2685-2687.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials.

Authors:  E C Miltner; L E Bermudez
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

2.  Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex.

Authors:  M A Bertram; C B Inderlied; S Yadegar; P Kolanoski; J K Yamada; L S Young
Journal:  J Infect Dis       Date:  1986-07       Impact factor: 5.226

3.  Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS.

Authors:  L S Young; L Wiviott; M Wu; P Kolonoski; R Bolan; C B Inderlied
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

4.  Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Petrofsky; P Aralar; M Wu; L S Young
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

5.  Thiacetazone: in vitro activity against Mycobacterium avium and M. tuberculosis.

Authors:  L B Heifets; P J Lindholm-Levy; M Flory
Journal:  Tubercle       Date:  1990-12

6.  Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.

Authors:  L E Bermudez; P Kolonoski; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 7.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

8.  Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team.

Authors:  R E Chaisson; C A Benson; M P Dube; L B Heifets; J A Korvick; S Elkin; T Smith; J C Craft; F R Sattler
Journal:  Ann Intern Med       Date:  1994-12-15       Impact factor: 25.391

9.  Infection with Mycobacterium avium complex in patients without predisposing conditions.

Authors:  D S Prince; D D Peterson; R M Steiner; J E Gottlieb; R Scott; H L Israel; W G Figueroa; J E Fish
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

10.  Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods.

Authors:  C B Inderlied; L S Young; J K Yamada
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191
View more
  13 in total

1.  Exposure of mycobacteria to cell wall-inhibitory drugs decreases production of arabinoglycerolipid related to Mycolyl-arabinogalactan-peptidoglycan metabolism.

Authors:  Yoann Rombouts; Belinda Brust; Anil K Ojha; Emmanuel Maes; Bernadette Coddeville; Elisabeth Elass-Rochard; Laurent Kremer; Yann Guerardel
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

2.  Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384.

Authors:  Iman Halloum; Albertus Viljoen; Varun Khanna; Derek Craig; Christiane Bouchier; Roland Brosch; Geoffrey Coxon; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 3.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

4.  Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.

Authors:  Thomas Grau; Petra Selchow; Marcel Tigges; Reto Burri; Marc Gitzinger; Erik C Böttger; Martin Fussenegger; Peter Sander
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

5.  SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.

Authors:  Luiz E Bermudez; Peter Kolonoski; Lianne E Seitz; Mary Petrofsky; Robert Reynolds; Martin Wu; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  CC chemokine receptor (CCR)-2 prevents arthritis development following infection by Mycobacterium avium.

Authors:  Marlon P Quinones; Fabio Jimenez; Hernan Martinez; Carlos A Estrada; Opal Willmon; Molly Dudley; William A Kuziel; Peter C Melby; Robert L Reddick; Sunil K Ahuja; Seema S Ahuja
Journal:  J Mol Med (Berl)       Date:  2006-03-07       Impact factor: 4.599

Review 7.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851

8.  EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.

Authors:  Lynn G Dover; Anuradha Alahari; Paul Gratraud; Jessica M Gomes; Veemal Bhowruth; Robert C Reynolds; Gurdyal S Besra; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

Review 9.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

10.  Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues.

Authors:  Geoffrey D Coxon; Derek Craig; Rosa Milagros Corrales; Emilie Vialla; Laila Gannoun-Zaki; Laurent Kremer
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.